Monroe facility ramp-up delays
Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.
high · management_commentary
Glenmark Pharmaceuticals Limited — Q3 FY24
Glenmark's Q3 FY24 consolidated revenue fell 16% YoY to INR 29,096 million, primarily due to a one-time India distribution restructuring that reduced channel inventory.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. respiratory launch timeline uncertainty
Generic Flovent pMDI NDA filing expected in Q1 FY25, but approval and launch timing remain uncertain, affecting U.S. growth trajectory.
medium · management_commentaryIndia business recovery may be slower than guided
Despite guidance of INR 1,000 crore quarterly run rate, the one-time restructuring impact may have lingering effects on channel dynamics.
medium · analyst_question